

PRESS RELEASE
Uppsala
October 9, 2008

Q-Med gives notice to 50 of the co-workers in Uppsala

As part of the company's work on focussing resources on the esthetics business, personnel reductions will be made at Q-Med's facility in Uppsala.

As has been previously announced, Q-Med has decided to focus on the esthetics business. Sales and marketing of Hospital Healthcare products will be done via partners and there will be no further in-house development of new products within this area. This change leads to redundancies at Q-Med's facility in Uppsala. Despite the fact that Q-Med assesses that some of these redundancies can be absorbed by the esthetics business, approximately 50 of the co-workers in Uppsala will need to leave the company.

Negotiations will be initiated with union representatives immediately.

Q-Med continues to have a positive view of the market for the company's products. Furthermore, Q-Med assesses that the company will return to historical profitability levels within the Esthetics product area and that the Hospital Healthcare product area will display good profitability as a result of the above measures.

Queries should be addressed to:

Bengt Ågerup, President and CEO

Tel: + 46 (0)70 974 90 25

Alexander Kotsinas, Vice President and CFO

Tel: + 46 (0)73 500 11 11

Madelene Sandgren, Director Investor Relations and Corporate Communications,

Tel: + 46 (0)70 974 90 15

Q-Med AB is a rapidly growing and profitable biotechnology/medical device company. The company develops, manufactures, markets, and sells primarily medical implants. The majority of the products are based on the company's patented technology, **NASHA™**, for the production of stabilized non-animal hyaluronic acid. The product portfolio today contains: **Restylane®** for filling lines and folds, contouring and creating volume in the face, **Macrolane™** for body contouring, **Durolane™** for the treatment of osteoarthritis of the hip and knee joints, **Deflux®** for the treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children, and **Solesta™** for the treatment of fecal incontinence. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q-Med today has just over 700 coworkers, with close to 500 at the company's head office and production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid Cap segment of the OMX Nordic Exchange in Stockholm.

Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate identity number 556258-6882.
Tel: +46(0)18-474 90 00. Fax: +46(0)18-474 90 01. E-mail: info@q-med.com. Web: www.q-med.com.

In USA, Q-Med AB's affiliate is the wholly-owned subsidiary Q-Med Scandinavia, Inc.